At the 24th Congress of the European Hematology Association (EHA), Stefano Luminari from the University of Modena and Reggio Emilia, IT, discusses use of FDG-PET to guide the treatment of patients with follicular lymphoma (FL).
FDG-PET is used commonly in assessment of response in Hodgkin lymphoma and diffuse large B-cell lymphoma (DLBCL). It's use in FL has been investigated both retrospectively and prospectively. The quality of response measured by FDG-PET, after standard immuno-chemotherapy, predicts individual relapse risk and progressive disease after induction and also in the maintenance setting. In this interview, Stefano Luminari discusses existing data, and the ongoing trials in this setting. The results of these trials will confirm whether response-adapted therapy based on the metabolic achievement of complete response is beneficial to the patients.